Biosimilars 101: considerations for U.S. oncologists in clinical practice.

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Biosimilars, highly similar but not identical to reference biologics, are emerging for cancer treatments.
• Manufacturing complexities and cell line differences can lead to variations between biosimilars and reference products.

Purpose of the Study:

• To outline the regulatory pathway for U.S. biosimilar approval.
• To discuss considerations for oncologists regarding biosimilar use, including interchangeability, safety monitoring, and cost.

Main Methods:

• Regulatory pathway based on comparative analytical and clinical studies.
• Evaluation of evidence for interchangeability beyond initial approval.
• Consideration of indication extrapolation by the FDA.

Main Results:

• Biosimilars require rigorous characterization to demonstrate no clinically meaningful differences.
• Interchangeability designation, allowing pharmacy substitution, requires additional evidence.
• Post-approval safety monitoring is crucial due to potential structural changes and immunogenicity.

Conclusions:

• Oncologists need a broad understanding of biosimilar characteristics, regulatory approvals, and safety monitoring.
• Careful evaluation of potential cost savings, supply reliability, and patient support programs is necessary.
• The complexity of biologics necessitates robust safety surveillance for biosimilars in cancer care.